Herpes simplex virus (HSV) glycoproteins gE and gI form an immunoglobulin G (IgG
Herpes simplex virus (HSV) establishes latency within sensory ganglia and periodically reactivates to produce recurrent infections. Latency is one mechanism used by HSV to evade immune attack, since during latency few if any viral proteins are produced and the virus remains hidden from the host. But how does the virus evade host immunity during recurrent infection? Virus can generally be recovered from lesions for several days after reactivation despite an already primed immune system. HSV encodes at least 11 glycoproteins (48) , several of which are essential for virus replication since they mediate virus entry or egress (30, 40, 53) . Others are nonessential for replication in vitro yet are conserved in nature, suggesting an important role in vivo. Glycoproteins gE and gI are among the nonessential HSV glycoproteins. gE and gI form a hetero-oligomer complex that functions as a receptor for the Fc domain of immunoglobulin G (IgG) (5, 32, 33, 41) . gE alone acts as a lower affinity IgG Fc receptor (Fc␥R), binding IgG aggregates but not IgG monomers, while the gE-gI complex acts as a higheraffinity Fc␥R, binding both IgG monomers and aggregates (6, 12) .
IgG Fc␥Rs are fairly widely distributed among human pathogens. Cells infected by HSV type 2 (HSV-2) (42), varicella-zoster virus (36) , and cytomegalovirus (37) express virusencoded IgG Fc␥Rs. Certain protozoa (schistosomes and trypanosomes) (15, 50) and bacteria (for example, staphylococci [protein A] and streptococci [protein G]) (7, 47 ) also express IgG Fc binding proteins. Therefore, understanding the role of the HSV-1 Fc␥R in immune evasion may have broad implications for understanding microbial pathogenesis.
Initial studies of the HSV Fc␥R focused on its role in binding nonimmune IgG (1, 8, 11) ; however, the Fc␥R preferentially binds anti-HSV IgG by a process called antibody bipolar bridging (16, 51) . This occurs when an HSV antibody molecule binds to its antigenic target by its Fab end and the Fc domain of the same molecule binds to the HSV-1 Fc␥R. In vitro studies indicate that the HSV Fc␥R inhibits complement-enhanced antibody neutralization (16) , antibody-dependent cellular cytotoxicity (13) , and attachment of granulocytes to the Fc domain of antibodies on HSV-infected cells (51) . These results support a possible role for the Fc␥R in immune evasion and form the basis for studying the biologic relevance of the HSV-1 Fc␥R in vivo.
gE and gI play an important role in virus spread from cell to cell (2, 9, 10) . This has created an obstacle to investigate the role of the HSV-1 Fc␥R in pathogenesis, since HSV-1 gE or gI null viruses are practically avirulent (2, 10, 43) , probably because of their inability to spread. Therefore, to study the role of the Fc␥R in virulence it was necessary to develop HSV-1 mutant viruses that are deficient in Fc binding while retaining other gE and gI functions. Using this rationale, an HSV-1 mutant virus that has a four-amino-acid insert within the gE IgG Fc binding domain was generated (3, 14) . This Fc␥R Ϫ virus remained intact for virus spread at the skin inoculation site in mice and caused disease comparable in severity to that caused by wild-type and marker-rescued viruses. In the presence of anti-HSV IgG, the Fc␥R Ϫ virus was significantly more susceptible to antibody attack than Fc␥R ϩ strains, indicating that the HSV Fc␥R promotes immune evasion in vivo.
MATERIALS AND METHODS
Cells and antibodies. African green monkey kidney cells (Vero) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 20 g of gentamicin per ml, and 20 mM HEPES (pH 7.3). Anti-gE monoclonal antibody (MAb) 1BA10 (17) and anti-gI MAb Fd69 (39) were previously described. Pooled human IgG (165 mg/ml) was purchased from the Michigan Department of Public Health, Lansing. This reagent is prepared by pooling serum from thousands of normal donors. Characteristics of the pooled human anti-HSV IgG are as follows: anti-HSV-1 enzyme-linked immunosorbent assay (ELISA) titer, 1:150,000; anti-gE ELISA titer, 1:30,000, anti-gI ELISA titer, 1:10,000; neutralizing antibody titer against wild-type or Fc␥R Ϫ mutant virus in the absence of complement, 100 g/ml. In addition, by Western blot analysis, human anti-HSV IgG recognizes purified HSV-1 glycoproteins gC, gD, gE, and gH, and in an immunoprecipitation assay the IgG reacts comparably with wildtype gE and a mutant form of gE that has four amino acids inserted at position 339. The human anti-HSV IgG nonimmune serum was obtained from HSV-1-and HSV-2-seronegative donors (18) and purified on a protein G affinity column (Sigma Chemical Co., St. Louis, Mo.). Murine anti-HSV serum was pooled from mice 2 to 4 weeks after recovering from wild-type HSV-1 flank infection. IgG was purified from serum on a protein A affinity column (Bio-Rad Laboratories, Hercules, Calif.). The neutralizing titer of murine anti-HSV IgG in the absence of complement was 50 g/ml against wild-type and Fc␥R Ϫ mutant virus. Viruses. Wild-type HSV-1 strain NS is a low-passage-number clinical isolate and was used for the generation of mutant viruses (18) . To construct a gE null virus (NS-gE null ), the entire gE coding sequence was excised from pCMV3gE-1 with XbaI and cloned into pSPT18 (14) . A 1.1-kb HpaI-BglII fragment from amino acids 124 to 508 (Fig. 1B) was excised, and the HpaI site was changed to a BglII site. A 4.3-kb fragment derived from pD6P (22) containing the Escherichia coli ␤-galactosidase gene under the control of the HSV ICP6 promoter was cloned into the BglII site. The resultant vector contains 374 bp of NS DNA sequences 5Ј and 225 bp 3Ј of the ICP6::lacZ cassette and was used to construct the gE null virus. The XbaI fragment containing the flanking sequence vector was isolated, and 750 ng was cotransfected into Vero cells with 1.0 g of NS DNA by the calcium phosphate transfection method. Four hours later, the DNA-calcium phosphate mixture was removed and cells were shocked with 15% glycerol. Cells were harvested when cytopathic effects were noted in 30 to 40% of cells, and cells were sonicated to prepare a virus pool. Recombinant gE null virus expressing ␤-galactosidase was selected by infecting Vero cells and overlaying with 0.5% agarose, 5.0% fetal bovine serum, and 300 g of 5-bromo-D-galactopyranoside (X-Gal). Blue plaques were picked and purified twice in X-Gal agarose overlay and once by limiting dilution. Virus was purified from supernatant fluids of infected Vero cells on a 5 to 70% sucrose gradient.
Rescued virus, rNS-gE null , was prepared by cotransfection of Vero cells with 1.0 g of NS-gE null DNA and 1.5 g of wild-type gE fragment purified from pCMV3gE-1 (14) . Progeny viruses were examined by immunoperoxidase staining using anti-gE MAb 1BA10 to confirm expression of gE on the surface of infected cells (29) . Plaques were purified by limiting dilution, and virus pools were prepared. gE linker insertion plasmids H339 and H406 (14) were used to generate recombinant viruses NS-gE 339 and NS-gE 406 , respectively. Plasmid H339 has a four-amino-acid XhoI linker inserted after gE amino acid 339, which is within the IgG Fc binding domain (3, 14) . Plasmid H406 contains the same four amino acids inserted after gE amino acid 406, which lies outside the IgG Fc binding domain (Fig. 1B) (3, 14) . To construct recombinant viruses, 1.0 g of NS-gE null DNA was cotransfected with 1.5 g of plasmid H339 or H406, and recombinants were selected by immunoperoxidase staining using anti-gE MAb 1BA10 and purified by limiting dilution.
Marker rescue of NS-gE 339 virus was accomplished by cotransfecting Vero cells with virus DNA from NS-gE 339 and wild-type gE DNA purified from pCMV3gE-1. Virus was harvested and used to infect cells in a 48-well plate at a concentration of 0.5 to 1 PFU/well. Virus was expanded from wells containing single plaques that were screened for rescue of Fc␥R activity by using biotinlabeled nonimmune monomeric IgG, which was incubated with infected cells for 30 min at 4°C and then reacted with strepavidin-phycoerythrin (4). Viruses positive for immunofluorescence were purified three times by limiting dilution, and one clone, designated rNS-gE 339 , was chosen for further studies.
Southern blots were performed to confirm proper construction of mutant and rescued viruses. When infected Vero cells reached 100% cytopathic effects, DNA was extracted and 1.0 g of DNA was digested with NruI alone or NruI and XhoI to detect XhoI linkers in NS-gE 339 or NS-gE 406 . The blot was probed using a 1.1-kb HpaI-BglII fragment (Fig. 1B) deleted from gE in NS-gE null virus.
Fluorescence-activated cell sorting analysis. Double-label staining was performed to detect gE expression and IgG Fc binding. Vero cells were infected at a multiplicity of infection of 5 for 16 h and harvested by using cell dissociation buffer (Gibco BRL, Grand Island, N.Y.). Cells were incubated for 60 min at 4°C with anti-gE MAb 1BA10 and biotin-labeled nonimmune monomeric human IgG (50 g/ml). Cells were washed and then incubated with fluorescein isothiocyanate (FITC)-conjugated goat F(abЈ) 2 anti-mouse IgG and strepavidin-phycoerythrin for 60 min at 4°C, fixed in 1% paraformaldehyde, and analyzed by dual-channel immunofluorescence (FACScan; Becton Dickinson). To detect gI expression, infected Vero cells were incubated with anti-gI MAb Fd69 (39) and FITC-conjugated goat F(abЈ) 2 anti-mouse IgG.
Complement-enhanced antibody neutralization. Assays were performed by incubating 10 4 to 10 5 PFU of wild-type or mutant viruses with anti-HSV pooled human IgG at a concentration (100 g/ml) that neutralized 50% of the virus in the absence of complement (16) . Ten percent human serum obtained from an HSV-1-and HSV-2-seronegative donor, or heat-inactivated serum as a control, was added as source of complement for 60 min at 37°C, and titers were determined by plaque assay on Vero cells. Complement-enhanced antibody neutralization results are expressed as titer (log 10 ) when virus is incubated with antibody plus heat-inactivated complement minus titer (log 10 ) when virus is incubated with antibody plus active complement.
Murine flank model. The shaved right flanks of 5-to 6-week-old female BALB/c mice were denuded by using a depilatory cream. Twenty-four hours later, virus (5 ϫ 10 3 to 5 ϫ 10 5 PFU) in 10 l of sterile Dulbecco modified Eagle medium was applied to the denuded flank several millimeters from the spinal column and scratched gently 30 times with a 27-gauge needle in an approximate 3-by 3-mm area (45, 46) . Disease scores were recorded daily and expressed as the sum of the scores from days 3 to 8 postinfection. Disease at the inoculation site was scored as follows: 0 points for no disease; 0.5 for swelling without vesicles; 1.0 point for each vesicle or scab to a maximum daily score of 5 points. If vesicles or scabs became confluent, points were assigned based on the size of the confluent lesion. Swelling and lesions at locations separate from the site of inoculation were considered dermatomal or zosteriform lesions. Scoring of these lesions was the same as at the inoculation site except that a maximum daily score of 10 was used since a larger number of lesions could be counted over the greater skin area involved.
Mice were passively immunized intraperitoneally (44, 46) with pooled human anti-HSV IgG, murine anti-HSV IgG, or nonimmune human IgG 16 h prior to flank infection. Animals were scored for disease at the inoculation and zosteriform spread sites. Passive transfer experiments were performed with 200, 500, or 2,000 g of IgG/mouse, concentrations which were selected based on previous reports using human antibodies for passive protection (24) .
Viral titers of skin lesions. Mice were euthanized, and a 0.5-cm 2 area of skin was excised from the inoculation site 1, 2, 3, or 5 days postinfection and stored at Ϫ70°C. Skin samples were thawed and Dounce homogenized, and virus titers were determined on Vero cells.
RESULTS

Characterization of HSV-1 gE mutant viruses.
We previously reported that gE mutant viruses NS-gE null and NS-gE 339 are Fc␥R Ϫ , and that NS-gE 339 has a cell-to-cell spread phenotype similar to that of wild-type virus in epidermal keratinocyte (HaCaT) cells (52) . We now report results that confirm proper construction of gE null virus NS-gE null , gE mutant viruses NS-gE 339 and NS-gE 406 , and gE rescued viruses rNS-gE null and rNS-gE 339 , and we define the importance of the HSV-1 Fc␥R in immune evasion by examining in vitro and in vivo characteristics of NS-gE 339 .
A Southern blot was prepared from viral DNA digested with NruI or NruI plus XhoI to demonstrate XhoI linkers inserted in gE (Fig. 1A) . The blot was probed with a 1.1-kb HpaI-BglII gE fragment deleted from NS-gE null (Fig. 1B) . Following NruI digestion, a 2.4-kb fragment containing the entire gE protein coding sequence was detected in all viruses except NS-gE null (Fig. 1A, lanes 1 to 6) . Digestion with NruI and XhoI revealed two DNA gE-1 fragments in NS-gE 339 and NS-gE 406 , indicating the presence of XhoI linkers at the expected positions in these viruses (Fig. 1A, lanes 10 and 12) . The absence of XhoI linkers in rNS-gE 339 indicates rescue of this mutant (Fig. 1A,  lane 11) . To confirm that NS-gE null contains the ICP6::lacZ gene, DNA was digested with NruI and analyzed by Southern blotting using lacZ as a probe. The expected 6.4-kb fragment was detected (result not shown). When the blot was probed with the 374-bp 5Ј gE-1 flanking sequence, the lacZ insert was demonstrated to be within gE (result not shown).
NS-gE 339 is a gE ؉ gI ؉ Fc␥R ؊ mutant virus. A number of Fc␥R Ϫ viruses have been studied previously (2, 9, 10); however, mutant viruses were gE null, which complicates efforts to separate Fc␥R activity from other functions mediated by gE. Double-label flow cytometry was performed to measure both Fc␥R activity and gE expression at the surface of cells infected with wild-type, gE mutant, or rescued viruses (Fig. 2) . NS expresses gE and binds IgG ( Fig. 2A) . NS-gE null does not express gE or bind IgG (Fig. 2B) . NS-gE 339 expresses gE but does not bind IgG (Fig. 2C) , indicating that this mutant virus is gE ϩ Fc␥R Ϫ . This was anticipated since the mutation was created within the gE Fc binding domain (Fig. 1B) . NS-gE 406 expresses gE and binds IgG (Fig. 2D) , indicating that this mutant virus is gE ϩ Fc␥R ϩ , which was expected since the mutation was outside the gE Fc binding domain (Fig. 1B) . rNS-gE null expresses gE and binds IgG (Fig. 2E) infected cells are more susceptible to activities mediated by the IgG Fc domain, including complement activation and antibody-dependent cellular cytotoxicity (13, 16) . We tested whether Fc␥R Ϫ virus NS-gE 339 is capable of antibody bipolar bridging by measuring its susceptibility to complement in an assay that detects complement-enhanced antibody neutralization (Fig. 3A) . To this end, 10 4 to 10 5 PFU was incubated with human anti-HSV IgG and active complement, or heat-inactivated complement as a control, and the neutralization mediated by of the addition of complement was measured. Human anti-HSV IgG was used at a concentration of 100 g/ml, which was the titer that neutralized 50% of each virus strain. Fc␥R ϩ viruses NS, rNS-gE 339 , and rNS-gE null showed only 0.2-to 0.5-log 10 (2-to 3-fold) additional neutralization when complement was added to human HSV antibodies, while Fc␥R Ϫ viruses NS-gE 339 and NS-gE null demonstrated 2-to 2.1-log 10 (100-to 126-fold) additional neutralization in the presence of complement (P Ͻ 0.01, Fc␥R Ϫ viruses compared with the Fc␥R ϩ strains) (Fig. 3B) . As controls, viruses were incubated with antibody or complement but not both. Differences in neutralization among the viruses emerged only when viruses were incubated with antibody plus complement. As an additional control, viruses were incubated with murine anti-HSV IgG. The HSV-1 Fc␥R binds the Fc domain of human, but not murine, IgG (31); therefore, the viral Fc␥R should not protect against complement-enhanced antibody neutralization using murine IgG as the source of antibody (16) . When the panel of viruses was incubated with murine antibody plus complement, no differences were detected among the viruses (result not shown). Therefore, we conclude that the four-amino-acid insert in NS-gE 339 renders the virus incapable of antibody bipolar bridging and that the NS-gE 339 mutant virus is as susceptible to complement-enhanced antibody neutralization as is NS-gE null virus.
NS-gE 339 causes disease at the inoculation site in the mouse flank model. Previous studies showed that gE null viruses are virtually avirulent (43) , likely because gE is required for virus spread (2, 10). Our intent was to develop an Fc␥R Ϫ mutant virus that remained intact for cell-to-cell spread so that we could separate the multiple functions mediated by gE. We hypothesized that experiments using mice may enable us to separate Fc␥R and cell spread functions, since murine IgG Fc does not bind to the HSV Fc␥R (31) . Therefore, the absence of an Fc␥R should have no impact on disease in mice.
Fc␥R Ϫ virus NS-gE 339 was scratched onto the flanks of mice, and the skin lesions at the inoculation site were counted. At an inoculum of 5 ϫ 10 5 PFU, NS-gE 339 produced disease scores comparable to those of NS, NS-gE 406 , and rNS-gE 339 , while NS-gE null produced few lesions (each virus compared with NS-gE null , P Ͻ 0.001) (Fig. 4A) . Additional experiments were performed with wild-type, NS-gE 339 , and rNS-gE 339 viruses to 
viruses NS, rNSgE 339 , and rNS-gE null and Fc␥R
Ϫ viruses NS-gE 339 and NS-gE null . Each virus was incubated with pooled human IgG at 100 g/ml, which resulted in 50% neutralization in the absence of complement. Then 10% nonimmune human serum or heat-inactivated serum was added, and complement-enhanced neutralization was calculated by determining the additional neutralization mediated by including complement in the reaction. Results are the mean (Ϯ SEM) of three experiments.
determine if NS-gE 339 produced comparable disease scores over a range of inocula. Figure 4B demonstrates that disease scores were similar for the three viruses when inoculated at 10-and 100-fold-lower doses. We conclude that Fc␥R Ϫ mutant virus NS-gE 339 differs from previously described gE mutants since it produces disease similar to those produced by wild-type and rescued viruses at the inoculation site.
In the flank model, HSV-1 travels from the skin to the dorsal root ganglia and then returns to the skin by axonal transport to produce lesions in a zosteriform distribution (45, 46) . Animals infected with NS, rNS-gE 339 , NS-gE 339 , or NS-gE null were scored for zosteriform spread disease. NS-gE null caused no disease, most likely because of defective spread. Fc␥R Ϫ mutant NS-gE 339 produced zosteriform lesions (at 5 ϫ 10 5 PFU, NS-gE 339 lesion scores were 21.5 Ϯ 3.5 compared with NSgE null score of 0; P Ͻ 0.001); however, NS-gE 339 caused less disease than NS, NS-gE 406 , or rNS-gE 339 (NS scores were 41.5 Ϯ 1.8, NS-gE 406 scores were 37.3 Ϯ 1.6, and rNS-gE 339 scores were 38 Ϯ 1.9; P Ͻ 0.01 compared with NS-gE 339 ). Thus, NS-gE 339 is intact for cell spread at the skin inoculation site; however, the virus may be partially defective in neuronal spread. In support of a possible neuronal spread defect is the observation that zosteriform lesions developed on average 1.3 to 1.4 days later in animals infected with NS-gE 339 than rNSgE 339 (Fig. 5A) . We conclude that HSV antibody is significantly more effective in reducing disease scores of Fc␥R Ϫ than Fc␥R ϩ viruses. Mice were passively immunized with 200 or 2,000 g of nonimmune human IgG to determine if antibodies must be capable of antibody bipolar bridging to have a greater effect on Fc␥R Ϫ than Fc␥R ϩ viruses. The IgG Fc domain of nonimmune IgG can bind to the HSV-1 Fc␥R; however, the Fab domain does not bind to HSV antigens, and therefore nonimmune IgG is not capable of bipolar bridging. Nonimmune IgG had little effect on disease (Fig. 5B) . Since nonimmune human IgG did not modify HSV-1 disease, we conclude that a more important function of the HSV-1 Fc␥R is to block activities of the Fc domain of anti-HSV IgG.
As an additional control, mice were passively immunized with murine anti-HSV-1 IgG inoculated at 200 or 2,000 g/ mouse. This antibody is also not capable of antibody bipolar bridging because the Fc domain of murine IgG does not bind to the HSV-1 Fc␥R (31). We postulated that murine anti-HSV IgG would have equal effects on Fc␥R Ϫ and Fc␥R ϩ viruses. Results shown in Fig. 5C support our hypothesis. We conclude that the role of the HSV-1 Fc␥R is to protect the virus or virus-infected cell against human anti-HSV IgG.
To further demonstrate a role for the HSV-1 Fc␥R in immune evasion, viral titers were performed on skin excised from the inoculation site. Animals were passively immunized with human anti-HSV IgG at 500 g/animal, or saline as control, and then infected with wild-type or NS-gE 339 virus (Fig. 6A) . NS and NS-gE 339 viruses grew to similar titers in saline control animals, which indicates that there is no defect in NS-gE 339 replication in skin. Anti-HSV IgG had little effect on NS titers but had a dramatic effect on NS-gE 339 titers. By day 1 postinfection, NS-gE 339 titers were approximately 10-fold lower in antibody-treated animals than in saline controls, and by day 3, differences in titers reached approximately 10,000-fold (P Ͻ 0.01). Virus titers at day 3 were also measured in animals infected with rescued strain, rNS-gE 339 . Virus titers in salinetreated controls were 5.2 log 10 Ϯ 0.1 (1.6 ϫ 10 5 PFU/ml), compared with 4.6 log 10 Ϯ 0.1 (4 ϫ 10 4 PFU/ml) in animals treated with human anti-HSV IgG (mean Ϯ standard error of the mean [SEM] of four animals each). Thus, the rescued strain showed fourfold differences in titers between antibodytreated and untreated animals. This contrasts sharply with the Fc␥R Ϫ mutant strain, which showed 10,000-fold differences. Additional studies comparing the effects of murine anti-HSV IgG on virus titers in animals infected with Fc␥R Ϫ mutant or rescued virus were performed (Fig. 6B) . At 3 days postinfection, murine anti-HSV IgG had similar effects on the two virus strains, showing an approximate 2-log 10 decrease in titers. We conclude that the Fc␥R provides marked protection to the virus or infected cell against human, but not murine, anti-HSV IgG.
DISCUSSION
Studies to define the biological relevance of the HSV-1 Fc␥R have been hampered by the fact that gE null viruses are markedly attenuated in vivo, probably because of defects in cell spread. The approach in the present study was to alter only a small region within the gE IgG Fc binding domain so that we could isolate an Fc␥R Ϫ mutant virus that retains other functions mediated by gE. We constructed gE mutant virus NSgE 339 , which has the following phenotype: gE ϩ , gI ϩ , negative for binding nonimmune monomeric IgG, negative for antibody bipolar bridging, and intact for producing lesions at the skin inoculation site. Therefore, Fc␥R Ϫ mutant virus NS-gE 339 has the phenotype required for in vivo studies to define the role of the HSV-1 Fc␥R in pathogenesis.
In prior experiments using cells transfected with gE linker insertion plasmids, we found that plasmid H339 did not form an Fc␥R, whereas cells transfected with plasmid H406 expressed an Fc␥R (3, 14) . When these mutant genes were introduced into the HSV genome, the resulting HSV-1 virus, NS-gE 339 , failed to demonstrate Fc␥R activity, while NS-gE 406 had Fc␥R activity similar to wild-type activity. These results indicate that the Fc␥R phenotypes of gE linker insertion plasmids H339 and H406 were maintained when recombined into virus.
The mutation at gE amino acid 339 causes loss of Fc␥R activity. This mutation lies within a cysteine-rich region of the molecule (Fig. 1B) , which could raise concerns about whether the gE protein was grossly malformed. However, we believe that the mutation disrupts the Fc␥R domain, as intended, for the following reasons. (i) The mutation at position 339 is within the gE domain homologous to the site on mammalian Fc␥RII that binds IgG (14, 28) , suggesting that this region is involved in IgG Fc binding. (ii) Prior studies using gD-gE fusion pro- teins demonstrated that a gE domain from amino acid 183 to 402 binds IgG (14) . This includes the cysteine-rich domain of gE, which suggests that amino acids in this region form the Fc␥R. Therefore, the mutation at position 339 is likely to be within the Fc binding domain. (iii) In NS-gE 339 , gE is expressed on the virus and at the infected cell surface. If the protein were grossly malfolded, we would not expect gE transport to remain intact. (iv) A four-amino-acid mutation at position 380, which is outside the cysteine-rich region, has been recombined into virus, and this mutant strain is also Fc␥R Ϫ (18a). This suggests that gross alterations in structure are not required to disrupt Fc␥R activity. (v) NS-gE 339 causes disease similar to that caused by wild-type virus in skin, while NS-gE null does not. If the mutation at 339 had grossly altered gE conformation, we would not expect virulence to remain intact in skin (2) . Therefore, we conclude that the mutation at position 339 alters Fc␥R activity because it disrupts the Fc binding domain.
Studies were performed with mice by using passive transfer of human anti-HSV IgG to determine if the HSV- Virus titers were measured in skin samples to support the conclusion that the HSV-1 Fc␥R promotes immune evasion. We noted marked differences in virus titers in skin of mice passively immunized with human anti-HSV IgG and infected with Fc␥R Ϫ virus. By day 3, NS-gE 339 titers were 10,000-fold lower in animals immunized with human anti-HSV IgG compared with saline controls. In contrast, anti-HSV IgG had little effect on wild-type virus titers, since only small differences were detected between antibody-treated and saline controls and these differences were not detected until day 5 postinfection. Titers of the two viruses were similar in saline-treated controls, which indicates that the differences between NS and NS-gE 339 cannot be explained by defective NS-gE 339 cell-to-cell spread in skin. As controls, virus titers were also measured at the inoculation site 3 days after infection of animals passively immunized with murine anti-HSV IgG. As expected, murine antibody had similar effects on Fc␥R ϩ and Fc␥R Ϫ viruses. Therefore, differences in animals treated with human anti-HSV IgG are attributable to the effects of the HSV-1 Fc␥R in modifying IgG Fc-mediated activity.
A role for gE in epidermal spread is supported by the findings that gE null virus produces little disease at the inoculation site and small plaques in epidermal cells (52) . In contrast, NS-gE 339 is intact for epidermal spread, since virus skin titers, inoculation site disease scores, and epidermal cell plaque size (52) are comparable to those for wild-type virus. However, NS-gE 339 causes less zosteriform spread disease than wild-type virus, suggesting that the mutant virus may be defective in epidermal-neuronal spread, neuronal transport, or transneuronal spread. Therefore, the gE domain interrupted by the mutation at position 339 disrupts spread in some cell types without affecting others, which suggests that different gE domains may mediate epidermal and neuronal spread.
Additional immune evasion strategies have been described for HSV-1. Glycoprotein gC binds complement components C3 and its enzymatic cleavage products, C3b, iC3b, and C3c (17, 34) . gC prevents the interaction of properdin with C3b (29) , and blocks C5 interaction with C3b (19, 34) . These activities inhibit activation of the complement cascade, thereby protecting HSV-1 from complement-mediated neutralization (18, 21, 25, 38) or HSV-infected cells from complement-mediated injury (23) . ICP47 is an immediate-early HSV-1 protein that interferes with the TAP (transporter associated with antigen processing) system, preventing HSV peptides from being expressed within the context of major histocompatibility complex class I antigens (20, 26, 49, 54) . ICP47 inhibits peptide expression in human but not mouse cells (49, 54) , while gC, gE, and gI also show species specificity for human immune proteins (18, 27, 31) . Proof that immune evasion is important in vivo has been hampered by the species specificity of the interactions between viral proteins and the immune system. To circumvent this, the approach taken in this study was to passively transfer human IgG into mice, which enabled an assessment of the importance of human IgG-Fc␥R interactions in pathogenesis.
Results of this study help explain why antibodies are relatively ineffective in modifying HSV infection; however, the experiments do not address which aspects of IgG Fc-mediated immunity, such as complement activation, antibody-dependent cellular cytotoxicity, or complement-dependent cellular cytotoxicity, are inhibited by the HSV-1 Fc␥R. Our results suggest that virus neutralization in the absence of complement does not account for the effects of antibodies, since serum obtained from mice passively immunized with human anti-HSV IgG at 200 g per mouse had a neutralizing titer of Ͻ1:8; nevertheless, this concentration had a marked effect on disease scores and viral titers of NS-gE 339 virus.
The passive transfer murine model mimics conditions that exist following HSV vaccination, in that antibodies are present prior to infection. A modification of the model can be used to more closely simulate conditions during reactivation infection by delaying passive immunization with anti-HSV IgG until virus reaches the ganglion. Rabbit corneal infection can also be used to define the role of the Fc␥R in reactivation disease, since virus reactivates spontaneously in this model (35) , and passive transfer of IgG is not necessary because rabbit IgG Fc binds to the HSV-1 Fc␥R (31). However, studies of reactivation disease will require an Fc␥R Ϫ mutant virus that is intact for spread from ganglion to skin so that the role of gE in Fc␥R activity and cell spread can be clearly distinguished. The experiments performed in this study define a role for the HSV-1 Fc␥R in antibody evasion but do not address whether the Fc␥R is most important during primary or reactivation infection.
The fact that the HSV-1 Fc␥R blocks the effectiveness of antibodies administered prior to infection raises important questions regarding vaccine strategies to prevent HSV disease. Will the HSV-1 Fc␥R reduce the effectiveness of vaccineinduced antibodies? If so, attempts to block HSV-1 immune evasion may require that gE and/or gI be included in a subunit vaccine. Vaccine strategies to block HSV Fc␥R activity may be difficult to develop, since despite the high titers of antibodies to gE and gI in the pooled human IgG used for passive transfer studies, the antibodies did not effectively block Fc␥R activity of wild-type virus. This was apparent in complement-enhanced antibody neutralization experiments that used pooled human IgG and in antibody passive transfer studies. In these experiments pooled human IgG did not block Fc␥R activity since Fc␥R ϩ virus did not escape antibody attack. Critical epitopes involved in forming the HSV Fc␥R may be inaccessible to the immune system, or perhaps the epitopes are immunologically privileged because of sequence homology with mammalian Fc␥Rs.
